Previous 10 | Next 10 |
REHOVOT, Israel, and HOBOKEN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today the promotions of Shavit Beladev to Vice President respons...
REHOVOT, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will host a virtual analysts and investors meeting on Tuesday, June 7...
Kamada Ltd. (KMDA) Q1 2022 Earnings Conference Call May 17, 2022 08:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Presentation Operator Greetings. Welcome to the Kamada Ltd. ...
Kamada press release (NASDAQ:KMDA): Q1 GAAP EPS of -$0.04 misses by $0.07. Revenue of $28.1M (+12.9% Y/Y) misses by $4.63M. The company continues to expect to generate FY2022 total revenues in the range of $125M to $135M, +20% to +30% Y/Y vs. consensus of $132.89M; EBITDA of 12% to 15% of tot...
First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year. Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 - $135 Million, Representing a 20% to 30% Increase over 2021 and EBITDA Margins Anticipated Between 12%-15%, More Than 2.5X over 2021 ...
REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovA...
Kamada (NASDAQ:KMDA) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is $0.03 (-50.0% Y/Y) and the consensus Revenue Estimate is $32.73M (+31.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions ...
REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2...
Kamada Ltd. (KMDA) Q4 2021 Earnings Conference Call March 15, 2022 8:30 A.M. ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Presentation Operator 00:05 Greetings and welcome to the ...
Kamada press release (NASDAQ:KMDA): Q4 GAAP EPS of -$0.11 misses by $0.10. Revenue of $31.47M (-0.1% Y/Y) beats by $9.56M. For further details see: Kamada GAAP EPS of -$0.11 misses by $0.10, revenue of $31.47M beats by $9.56M
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...